newzzz
Back to recent news

News Archive

Past news

DiaSorin Announces Completion of the Acquisition of Luminex Corporation

Saluggia, July 14, 2021 – DiaSorin S.p.A. (“DiaSorin”; FTSE MIB: DIA) announces it has completed the acquisition of Luminex Corporation (“Luminex”; NASDAQ: LMNX) for a price of USD 37.00 per share that corresponds to a total equity value of approximately USD 1.8 billion….

DiaSorin Molecular Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2, including the India B.1.617

Cypress, Calif. (May 21, 2021) – DiaSorin Molecular LLC announced today that it has released the Simplexa™ SARS-CoV-2 Variants Direct assay (RUO) to enable detection and discrimination of four SARS-CoV-2 mutations associated with circulating virus variants without requiring upfront RNA extraction….

DiaSorin Molecular Receives Additional BARDA Funding in Support of Submitting the Simplexa™ COVID-19 Direct and the Simplexa™ COVID-19 & Flu A/B Direct kits for FDA 510(k) Clearance

Cypress, California (USA) – January 13, 2021 – DiaSorin Molecular LLC, a subsidiary of DiaSorin S.p.A. (FTSE MIB:DIA), announced today that it has received additional federal funding from the Biomedical Advanced Research and Development Authority (BARDA),…

DiaSorin Molecular’s Simplexa™ COVID-19 Direct Molecular Test CE Marked for Saliva Specimens

Cypress, Calif. (September 17, 2020) – DiaSorin Molecular LLC announced today that it has attained CE Marking for the addition of saliva specimens for use with the Simplexa COVID-19 Direct assay….

DiaSorin Molecular receives FDA clearance for the Simplexa™ Flu A/B & RSV Direct Gen II Assay. A partner to run with the Simplexa™ COVID-19 Direct assay.

Cypress, Calif. (September 8, 2020) – DiaSorin Molecular LLC announced today that it has received FDA Clearance for its Simplexa™ Flu A/B & RSV Direct Gen II kit….